Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer

NCT00563316 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00563316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00563316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2008
Completion date
June 30, 2010
Enrollment
28 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer